Effectiveness of Cell Culture-Based Influenza Vaccine, 2023-2024.

Background: The cell culture-based inactivated influenza vaccine (ccIIV) was first approved for use in children aged 4-17 years in 2016 in the United States. The approved age indication for ccIIV was expanded to include children 6 months and older beginning the 2022-2023 season. There is limited real-world data on ccIIV effectiveness in children.

Seasonal Incidence of Human Metapneumovirus in High-Risk Adults With Medically Attended Acute Respiratory Illness in a Rural US Community.

Background: The burden of human metapneumovirus (hMPV) among community-dwelling high-risk adults is understudied. We calculate the cumulative incidence of outpatient hMPV in high-risk adults, over five consecutive winter respiratory virus seasons (2015-2016 through 2019-2020), and describe clinical characteristics of their illnesses.

Methods: We conducted a retrospective analysis of data and respiratory specimens from adults ≥ 18 years old originally participating in a test-negative study of influenza vaccine effectiveness.

Young adult perspectives on deciding to get human papillomavirus (HPV) vaccination in urban and rural communities: A qualitative research study.

Human papillomavirus (HPV) vaccination coverage in the US is lower than other recommended adolescent vaccines. Coverage is consistently lower in rural areas, compared to urban areas. Despite this, there exists relatively little evidence on perspectives of HPV vaccination during adolescence/young adulthood.

Long-term Neutralizing Antibody Levels Against Measles and Rubella Viruses Among Adults With 3 Doses of Measles-Mumps-Rubella Vaccine.

Background: A third dose of measles-mumps-rubella vaccine (MMR) may be administered for various reasons, but data on long-term immunity are limited. We assessed neutralizing antibody levels against measles and rubella among adults up to 11 years after receipt of a third MMR dose.

Methods: In this longitudinal study, healthy adults who received a third MMR dose as young adults (ages 18-28 years) were recalled around 5 years and 9-11 years after the third dose.

COVID-19 Booster Dose Reminder/Recall for Adolescents: Findings From a Health-Care System in Wisconsin.

Purpose: This study assessed efficacy of one-time COVID-19 booster reminder/recall for booster eligible adolescents in a health-care system in Wisconsin.

Methods: COVID-19 booster eligible patients aged 12-17 years were randomized 1:1 to receive one reminder/recall message from the health-care system using the parent's preferred communication method (intervention) or no reminder/recall (usual care) in May 2022.

Results: Reminder/recall was sent to 2,146/4,296 (50%) adolescent patients.